HC Wainwright Reiterates Buy Rating for AC Immune (NASDAQ:ACIU)

HC Wainwright restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report released on Wednesday morning, MarketBeat Ratings reports. HC Wainwright currently has a $16.00 target price on the stock.

Separately, BTIG Research assumed coverage on shares of AC Immune in a report on Friday, May 31st. They set a buy rating and a $8.00 price target on the stock.

AC Immune Price Performance

AC Immune stock opened at $3.69 on Wednesday. The company’s fifty day simple moving average is $3.43 and its 200-day simple moving average is $3.39. AC Immune has a 12 month low of $2.20 and a 12 month high of $5.14. The stock has a market cap of $364.94 million, a P/E ratio of -5.35 and a beta of 1.24.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. On average, equities research analysts expect that AC Immune will post -0.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in AC Immune in the second quarter worth $218,000. Renaissance Technologies LLC lifted its position in AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after acquiring an additional 136,300 shares during the last quarter. Vanguard Capital Wealth Advisors acquired a new position in AC Immune during the 2nd quarter worth $56,000. Assenagon Asset Management S.A. lifted its position in AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after acquiring an additional 328,312 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in AC Immune during the 2nd quarter worth $40,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.